References in periodicals archive ?
However, the exact mechanisms by which maternal obesity increases the risk of metabolic and cardiovascular disease in the offspring have not been established.
And to help people who already have cardiovascular disease, it should train a Heart Corps of thousands of non-physician specialists who would help motivate patients to adopt healthy lifestyles.
Possible benefits include reduced risk of cardiovascular disease, cancer, age-related macular degeneration and cataracts.
Researchers found in the early 1960s that the difference between the blood pressure taken from a person's arm and lower leg could predict future cardiovascular disease.
Patients benefit from the dual effect of folic acid, combined with primorine, a novel carbonyl-trapping combination, thus reducing the risk of developing cardiovascular disease.
These results confirm our in vitro observations and suggest that increased vasocontraction may be a contributing factor in the development of cardiovascular diseases in populations exposed to arsenic.
Endothelial dysfunction: implications for therapy of cardiovascular diseases.
Servier will be responsible for clinical development and commercialization of the products and will receive an exclusive worldwide license for any renin inhibitors discovered through the collaboration in the field of cardiovascular disease, including hypertension.
11 /PRNewswire/ -- Wyeth-Ayerst Laboratories, the world leader in women's health care, today expressed strong support for the American Heart Association's (AHA) call for action to prevent cardiovascular disease in women.
This coupled with the economic impact of cardiovascular disease underscores the need for new therapies that will reduce the suffering and improve the quality of life of individuals affected by this devastating disease.
Montano, President and CEO is presenting the progress of the company's drug candidates to treat cardiovascular disease at the 2006 UBS Global Life Sciences Conference.
OTCBB:CVBT) today announced that it has engaged The Bruckner Group (BGI) to help develop the value proposition for its drug candidates for the treatment of cardiovascular diseases formulated with Cardio Vascu-Grow(TM).

Full browser ?